Is axitinib/axitinib a targeted drug?

Axitinib/Axitinib is a targeted therapy drug mainly used to treat advanced renal cell carcinoma (RCC). As a tyrosine kinase inhibitor (TKI), axitinib inhibits the proliferation and growth of cancer cells by interfering with specific tyrosine kinase signaling pathways. Its mechanism of action is mainly to block the interaction between tumor cells and their growth signals, and to inhibit the formation of tumor new blood vessels. This process is called anti-angiogenesis.

Indications for axitinib generally include patients with advanced kidney cancer who have failed or relapsed after other treatments. In clinical applications, axitinib can be used as a first-line treatment drug, especially in some cases, it may be combined with immunotherapy drugs to improve the therapeutic effect. In addition, axitinib is also being evaluated in clinical trials in a number of other cancer types, and its potential applications are gradually expanding.

The drug targets different tyrosine kinases, such as vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and other tumor-related receptors, inhibiting the activity of these receptors, thereby reducing the blood supply and nutrient supply of the tumor, thereby inhibiting tumor growth and metastasis. The anti-angiogenic mechanism allows axitinib to play an important role in the tumor microenvironment, especially at the stage when tumors need to rely on new blood vessels to obtain nutrients and oxygen.

Clinical studies have shown that axitinib has significant efficacy, and common adverse reactions include hypertension, fatigue, oral ulcers, etc. These reactions are similar to most tyrosine kinase inhibitors. Therefore, during treatment with axitinib, patients need to regularly monitor blood pressure and other related indicators to ensure timely treatment of possible adverse reactions.

Reference materials:https://www.cancerresearchuk.org/about-cancer/treatment/drugs/axitinib